Citizens JMP Reiterates Market Outperform Rating on Acadia Pharmaceuticals (ACAD)

Citizens JMP analyst Jason Butler reiterated a Market Outperform rating and $38.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).

The analyst commented, "Phase 3 results for ACP-101 in Prader-Willi syndrome (PWS) expected in early 4Q25; we reiterate our Market Outperform rating and risk-adjusted, DCF-derived $38 price target on Acadia Pharmaceuticals. Acadia remains on track to report top-line results in early 4Q25 from the Phase 3 COMPASS-PWS trial evaluating ACP-101 to treat hyperphagia in patients with Prader-Willi syndrome. COMPASS-PWS has been optimized for success, notably through prioritizing the ACP-101 treatment dose that demonstrated efficacy in a previous Phase 3 study (3.2mg TID) and increasing treatment duration from 8 weeks to 12 weeks. We estimate potential upside of 20-30% on positive results (55% probability) and 10-15% downside on negative results (45% probability)."

For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.

Shares of Acadia Pharmaceuticals closed at $24.76 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)
• Aurora Spine settles patent dispute, secures $600K insider loan